1.91
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cognition Therapeutics Inc | CGTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.91 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.07 - 6.2686 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.91 | USD |
Cognition Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 55.37M | 28.99M | 21.85M | $ - | $ - | -3.13 | -0.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 3.21M | 0.30% |
Cognition Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CGTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.90 | 2.14 | 1.83 | 2.03 | 98,986 | 0.01 | 0.53% |
1 Month | 2.10 | 2.331 | 1.83 | 2.03 | 65,696 | -0.19 | -9.05% |
3 Months | 1.47 | 3.51 | 1.31 | 2.51 | 191,726 | 0.44 | 29.93% |
6 Months | 2.61 | 3.51 | 1.07 | 2.24 | 143,751 | -0.70 | -26.82% |
1 Year | 4.23 | 6.2686 | 1.07 | 2.95 | 211,159 | -2.32 | -54.85% |
3 Years | 12.15 | 13.80 | 1.07 | 3.91 | 186,434 | -10.24 | -84.28% |
5 Years | 12.15 | 13.80 | 1.07 | 3.91 | 186,434 | -10.24 | -84.28% |
Cognition Therapeutics Description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. |